













Estimated	Blood Volume
Age	Estimated blood volume (mL/kg)
Premature infant	90-100
Term infant to 3 months <sup>a</sup>	80-90
Infant/children>3 months	75
Obese children	65
Adolescent male	70
Adolescent female	65
N	
· · · · · · · · · · · · · · · · · · ·	s







Blood Transfusion Guideline			
Blood component/ product	Dose per kg	Anticipated increase	Treatment Threshold
Red blood cells	10 mL <sup>b</sup>	2g/dL (20g/L)	<8g/dL <sup>c</sup>
Frozen plasma	10 mL	Coagulation factors by 20%	INR>1.8
Platelets	10 mL	150×10 <sup>9</sup>	<50×10 <sup>9d</sup>
Cryoprecipitate	5 mL	Fibrinogen by 30mg/dL	<1.5g/L
Fibrinogen concentrate	20 mg	Fibrinogen by 30mg/dL	<1.5g/Lª
	25	le V	





KAS 1: Pediatricians and other pediatric health care providers (PHCPs) should treat acute pain using a multimodal approach that includes the appropriate use of nonpharmacologic therapies, nonopioid medications, and, when needed, opioid medications.       B       Strong         KAS 2: Pediatricians and other PHCPs should NOT prescribe opioids as monotherapy for children and adolescents when prescribing opioids for acute pain in children and adolescents, PHCPs should provide immediate-release opioid formulations, start with the lowest age and weight-appropriate dose, and provide an initial supply of 5 days or fewer, unless the pain is related to trauma or surgery with an expected duration of pain of more than 5 days.       C       Recommediate         KAS 4.1: When treating acute pain in children and adolescents younger than 12 years, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KAS 4.3: When treating acute pain in children and adolescents younger than 12 years, pediatricians and other       X       Strong         MAS 5.4: When treating acute pain in children and adolescents younger than 12 years, pediatricians and other       X       Strong         KAS 4.3: When treating acute pain in adolescents 12–18 years of age who have obesity, obstructive sleep apnea, or severe lung disease, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KAS 4.4: When treating osture pain in poople of any age who are breastfeeding, pediatricians and other PHCPS       X       Strong should NOT prescribe codeine or tramadol.         KAS 4.4: When treating acute pain in poople of any age who are breast	recommendation nendation recommendation recommendation			
KAS 2: Pediatricians and other PHCPs should NOT prescribe opioids as monotherapy for children and adolescents       B       Strong         who have acute pain.       KAS 3: When prescribing opioids for acute pain in children and adolescents, PHCPs should provide immediate- release opioid formulations, start with the lowest age- and weight-appropriate doses, and provide an initial supply of 5 days or fewer, unless the pain is related to trauma or surgery with an expected duration of pain of more than 5 days.       C       Recome         KAS 4.1: When treating acute pain in children and adolescents younger than 12 years, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KAS 4.2: When treating acute pain in adolescents 12–18 years of age who have obesity, obstructive sleep apnea, or severe lung disease, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KAS 4.4: When treating acute pain in adolescents 12–18 years of age who have obesity, obstructive sleep apnea, or severe lung disease, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KAS 4.4: When treating acute pain in people of any age who are breastfleeding, pediatricians and other PHCPS       X       Strong         KAS 4.4: When treating acute pain in children or adolescents who are taking sodating medications, such as should NOT prescribe codeine or tramadol.       X       Strong	recommendation nendation recommendation recommendation			
KAS 3: When prescribing opioids for acute pain in children and adolescents, PHCPs should provide immediate- release opioid formulations, start with the lowest age and weight-appropriate doses, and provide an initial supply of 5 days or fewer, unless the pain is related to trauma or surgery with an expected duration of pain of more than 5 days.       C       Recomming Recomming a start with the lowest age and weight-appropriate doses, and provide an initial supply of 5 days or fewer, unless the pain is related to trauma or surgery with an expected duration of pain of more than 5 days.       C       Recomming Recomming a start pain in children and adolescents younger than 12 years, pediatricians and other       X       Strong         HICPs should NOT prescribe codeine or tramadol.       KS 4.2: When treating acute pain in adolescents 12–18 years of age who have obesity, obstructive sleep apnea, or severe lung disease, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KS 4.4: When treating posturgical pain after tonsillectomy or adenoidectomy in children and adolescents younger than 18 years, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KS 4.4: When treating acute pain in people of any age who are treastfeeding, pediatricians, and other PHCPS       X       Strong should NOT prescribe codeine or tramadol.       X       Strong         KS 5: When treating acute pain in children or adolescents who are taking sedating medications, such as betwardiatznices and date PHCPs should use caution whom prescribing onlights       X       Strong	nendation recommendation recommendation			
KAS 4.1: When treating acute pain in children and adolescents younger than 12 years, pediatricians and other       X       Strong         PHCPs should NOT prescribe codeine or tramadol.       KAS 4.2: When treating acute pain in adolescents 12–18 years of age who have obesity, obstructive sleep apnea, or severe lung disease, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KAS 4.3: When treating posturgical pain after tonsilectomy or adenoidectomy in children and adolescents younger       X       Strong         than 18 years, pediatricians and other PHCPs should NOT prescribe codeine or tramadol.       X       Strong         KAS 4.4: When treating acute pain in people of any age who are breastfeeding, pediatricians and other PHCPS       X       Strong         should NOT prescribe codeine or tramadol.       X       Strong       Strong         KAS 5.4: When treating acute pain in people of any age who are breastfeeding, pediatricians, such as       X       Strong         should NOT prescribe codeine or tramadol.       X       Strong       Strong         KAS 5. When treating acute pain in children or adolescents who are taking sedating medications, such as       X       Strong         between discourse and ther PHCPs should we can who mean prescribing and the PHCPs       X       Strong	recommendation			
KAS 4.2: When treating acute pain in adolescents 12–18 years of age who have obesity, obstructive sleep apnea, or severe lung disease, pediatricians and other PHCPs should NOT prescribe codeline or tramadol.       X       Strong         KAS 4.3: When treating postsurgical pain after tonsillectomy or adenoidectomy in children and adolescents younger than 18 years, pediatricians and other PHCPs should NOT prescribe codeline or tramadol.       X       Strong         KAS 4.4: When treating acute pain in people of any age who are breastfeeding, pediatricians and other PHCPs       X       Strong should NOT prescribe codeline or tramadol.         KAS 4.4: When treating acute pain in people of any age who are breastfeeding, pediatricians and other PHCPs       X       Strong should NOT prescribe codeline or tramadol.         KAS 5: When treating acute pain in children or adolescents who are taking sedating medications, such as periodiatricians and other PHCPs should use prescribe oplicits.       X       Strong	recommendation			
KAS 4.3: When treating postsurgical pain after tonsillectomy or adenoidectomy in children and adolescents younger       X       Strong         than 18 years, pediatricians and other PHCPs should NOT prescribe codeline or tramadol.       X       Strong         KAS 4.4: When treating acute pain in people of any age who are breastfeeding, pediatricians and other PHCPS       X       Strong should NOT prescribe codeline or tramadol.         KAS 4.5: When treating acute pain in children or adolescents who are taking sedating medications, such as benzofiarerings and other PHCPs should use caution when prescribing onigids       X       Strong benzofiarerings and other PHCPs should use caution when prescribing onigids				
KAS 4.4: When treating acute pain in people of any age who are breastfeeding, pediatricians and other PHCPS       X       Strong should NOT prescribe codeine or tramadol.         KAS 5: When treating acute pain in children or adolescents who are taking sedating medications, such as       X       Strong benzöhlig context and other PHCPs should use caution when prescribing opinids	recommendation			
KAS 5: When treating acute pain in children or addesscents who are taking sedating medications, such as X Strong benzofiazenions pediatricians and other PKDEs should use caution when presenting onloids.	recommendation			
benzoarazepines, podrati foraris and other i nore should dee odation when presenting opticids.	KAS 5: When treating acute pain in children or adolescents who are taking sedating medications, such as X Strong recommendation benzodiazepines, pediatricians and other PHCPs should use caution when prescribing opioids.			
KAS 6: When prescribing opioids, pediatricians and other PHCPs should provide naloxone and counsel patients and X Recomming families on the signs of opioid overdose and on how to respond to an overdose.	KAS 6: When prescribing opioids, pediatricians and other PHCPs should provide naloxone and counsel patients and X Recommendation families on the signs of opioid overdose and on how to respond to an overdose.			
KAS 7: When prescribing opioids, pediatricians and other PHCPs should educate caregivers about safe storage and D Option directly observed administration of medications to children and adolescents.	KAS 7: When prescribing opioids, pediatricians and other PHCPs should educate caregivers about safe storage and D Option directly observed administration of medications to children and adolescents.			
KAS & When prescribing opioids, pediatricians and other PHCPs should educate caregivers about safe disposal of unused medications, help caregivers develop a plan to safely dispose of unused medications, and, if possible, offer safe disposal in their practice setting.	KAS 8: When prescribing opioids, pediatricians and other PHCPs should educate caregivers about safe disposal of unused medications, help caregivers develop a plan to safely dispose of unused medications, and, if possible, offer safe disposal in their practice setting.			
KAS 9: When treating acute, worsened pain in children and adolescents with preexisting chronic pain, pediatricians and other PHCPs should prescribe opioids when indicated and partner with any other opioid-prescribing clinicians involved in the patient's care and with specialists in chronic pain, palliative care, and/or other opioid stewardship programs to determine an appropriate treatment plan.       D       Option				





Devent Appropriate Dose, Immediate-Release Opioids
Opiate use among adolescents: Older age, Surgery type (PSF), and higher patient-reported pain.
Prescribe when:

Severe pain exists (pain scores of 7-10).
Severe pain is expected to occur and nonpharmacologic and non-opioid pain control is insufficient.
Opioids are expected to be effective.
The source of pain is known.

Prescribe at lowest effective dose for age and weight, and for the shortest duration needed. Ex. Oxycodone 0.1 to 0.2 mg/kg per dose Q4-6 hrs for children and adolescents <50 kg.</li>
Obese children, consult pharmacist - hydrophilic opioids (eg, oxycodone, morphine) dosed on IBW vs lipophilic opioids (eg, methadone) based on TBW.





















		Perioperative Management		
Evidence-based perioperative management of children with URTIs undergoing Elective Surgery.				
Premedication	Salbutamol (inhalational)	<ul> <li>Salbutamol puff 10–30 min before induction.</li> <li>2.5 mg if weight &lt;20 kg.</li> <li>5 mg if weight &gt;20 kg</li> </ul>		
Anaesthetic agents	Lidocaine (IV), 1.5 mg/kg Propofol Volatile anaesthetic agents	<ul> <li>To suppress airway reflexes either before intubation or extubation</li> <li>Propofol has good airway reflex blunting properties with mild bronchodilator effect</li> <li>Volatile anaesthetic agents have good bronchodilator properties but limited effects in suppressing airway reflexes.</li> <li>When using volatile anaesthetic agents sevoflurane followed by halothane anaesthetic agents.</li> <li>In high-risk children, IV induction with propofol over inhalational induction.</li> </ul>		
Extubation		<ul> <li>Optimal depth of anesthesia during intraoperative period</li> <li>Adequate suctioning under optimal depth of anesthesia.</li> <li>Awake extubation.</li> <li>Immediate oxygen supplementation and CPAP</li> </ul>		
Post operative		<ul> <li>Meticulous monitoring of SPO<sub>2</sub>, Oxygen supplementation via nasal prongs.</li> <li>Adequate hydration and analgesia</li> </ul>		
		* * *		











	The COLI	DS Score	
	1 point	2 points	5 points
Current signs and symptoms C	None	Mild (Parents confirm URI and/or congestion, rhinorrhea, sore throat, sneezing, low fever, dry cough)	Moderate / Severe (purulence, wet cough, abnormal lung sounds, lethargy, toxic appearance, or high fever)
Onset of symptoms O	>4 weeks ago	2 – 4 weeks ago	<2 weeks ago
Presence of lung diseases L	None	History of RSV, mild intermittent asthma, Bronchopulmonary dysplasia if >1 year old, loud snoring, or passive smoker.	Moderate / severe (moderate, persistant asthma, infant with Bronchopulmonary dysplasia, Obstructive sleep apnoea or pulmonary hypertension)
Airway device D	None or facemask	LMA or supraglottic airway	Endotracheal tube
Surgery S	Other (including PE tube)	Minor airway (T/A, nasal lacrimal duct probing, flexible bronchoscopy and dental extractions)	Major airway (cleft palate, rigid bronchoscopy, maxillofacial surgery)
	25	14	





References				
Kim, H. S., Kim, Y. S., Lim, B. G., Lee, J. H., Song, J., & Kim, H. (2022). Risk Assessment of Perioperative Respiratory Adverse Events and Validation of the COLDS Score in Children with Upper Respiratory Tract Infection. <i>Medicina</i> , 58(10), 1340 <u>https://doi.org/10.3390/medicina58101340</u>				
Laney J, Szokol JW. Managing COVID-19 in the perioperative setting. APSF Newsletter. 2022;37:62-63.				
Lema, G. F., Berhe, Y. W., Gebrezgi, A. H., & Getu, A. A. (2018). Evidence-based perioperative management of a child with upper respiratory tract infections (URTIs) undergoing elective surgery; A systematic review. <i>International Journal of Surgery Open</i> , 12, 17–24. <u>https://doi.org/10.1016/i.ijso.2018.05.002</u>				
Niermeyer, W. L., Ball, J., Worobetz, N., Bourgeois, T., Onwuka, A., Burrier, C., & Chiang, T. (2020). Respiratory viral panels and pediatric airway evaluation: The role of testing for upper respiratory infections to stratify perioperative risk. <i>International Journal of Pediatric Otorhinolaryngology</i> , 134, 110057–110057. https://doi.org/10.1016/j.ijporl.2020.110057				
Regli, A., Becke, K., & von Ungern-Sternberg, B. S. (2017). An update on the perioperative management of children with upper respiratory tract infections. <i>Current Opinion in Anaesthesiology</i> , 30(3), 362–367. <u>https://doi.org/10.1097/ACO.00000000000460</u>				
Tan, G. M., Murto, K., Downey, L. A., Wilder, M. S., & Goobie, S. M. (2023). Error traps in Pediatric Patient Blood Management in the Perioperative Period. Pediatric Anesthesia, 33(8), 609–619. <u>https://doi.org/10.1111/pan.14683</u>				
Templeton, T. W., Sommerfield, D., Hii, J., Sommerfield, A., Matava, C. T., Ungern-Sternberg, B. S., & Engelhardt, T. (2022). Risk assessment and optimization strategies to reduce perioperative respiratory adverse events in Pediatric Anesthesia—Part 2: Anesthesia-related risk and treatment options. <i>Pediatric Anesthesia</i> , 32(2), 217–227. https://doi.org/10.1111/pan.14376				
28				